Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remib…
Company previously disclosed settlement agreement in principle and fully provisioned for this resolutionBasel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Departme…
Company previously disclosed settlement agreement in principle and fully provisioned for this resolutionBasel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Departme…
As a leading healthcare company, Novartis is playing an important part by supporting vaccination to help overcome the pandemic. The safety of all associates, our customers, business partners and the communities where we run our operations remain a top …
Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile across the entire dose range testedAll doses provided cl…
Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities to address root causes of systemic disparities in h…
Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine …
New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1Patient satisfaction with 300 mg autoinjector was high – reaching 100% – with no new safety signals observed over 52 …
Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other measures1Complete control of CSU symptoms, assessed by a co…
Novartis announced today that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metast…
